Electric spectroscopy of vortex states and dynamics in magnetic disks

Spin-polarized radio frequency (RF) currents and RF-Oersted fields resonantly excite a magnetic vortex core confined in a micron-scale soft magnetic disk. In this study, we measured the rectifying voltage spectra caused by the anisotropic magnetoresistance oscillation due to the gyration of the vortex with different polarity and chirality. The measured spectra are presented such that we can determine the vortex properties and strength of the spin torques and Oersted field accurately and directly through analytical calculation.Comment: 39 pages,1 table, 10 figure

Luminosity dependence of the electron temperature in the bright hard state of the black hole candidate GX 339--4

We have analyzed 200 Rossi X-ray Timing Explorer observations of the black hole candidate GX 339--4, all from the bright hard state periods between 1996 and 2005. Purpose of our study is to investigate the radiation mechanisms in the hard state of GX 339--4. The broadband 3--200 keV spectra were successfully modeled by a simple analytic model, power--law with an exponential cut-off modified with a smeared edge. The obtained energy cut-off ($E_{\rm{cut}}$) was distributed over 50--200 keV, and the photon index over 1.4--1.7. We found a clear anti-correlation ($E_{\rm{cut}} \propto L^{-0.70\pm0.06}$) between the X-ray luminosity ($L$) in 2--200 keV and $E_{\rm{cut}}$, when $L$ is larger than $7 \times 10^{37}$ erg s$^{-1}$ (assuming a distance of 8 kpc), while $E_{\rm{cut}}$ is roughly constant at around 200 keV when $L$ is smaller than $7 \times 10^{37}$ erg s$^{-1}$. This anti-correlation remained unchanged by adopting a more physical thermal Comptonization model, which resulted in the anti-correlation that can be expressed as $kT_{\rm{e}} \propto L^{-0.24\pm0.06}$. These anti-correlations can be quantitatively explained by a picture in which the energy-flow rate from protons to electrons balances with the inverse Compton cooling.Comment: Accepted by PASJ. 15 pages, 8 figure

Mesoscopic bar magnet based on ε-Fe2O3 hard ferrite

Ferrite magnets have a long history. They are used in motors, magnetic fluids, drug delivery systems, etc. Herein we report a mesoscopic ferrite bar magnet based on rod-shaped ε-Fe2O3 with a large coercive field (>25 kOe). The ε-Fe2O3–based bar magnet is a single crystal with a single magnetic domain along the longitudinal direction. A wide frequency range spectroscopic study shows that the crystallographic a-axis of ε-Fe2O3, which corresponds to the longitudinal direction of the bar magnet, plays an important role in linear and non-linear magneto-optical transitions, phonon modes, and the magnon (Kittel mode). Due to its multiferroic property, a magnetic-responsive non-linear optical sheet is manufactured as an application using an ε-Fe2O3–based bar magnet, resin, and polyethylene terephthalate. Furthermore, from the viewpoint of the large coercive field property, we demonstrate that a mesoscopic ε-Fe2O3 bar magnet can be used as a magnetic force microscopy probe

Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide

<p>Abstract</p> <p>The risk of cardiovascular complication in a diabetes patient is similar to that in a nondiabetic patient with a history of myocardial infarction. Although intensive control of glycemia achieved by conventional antidiabetic agents decreases microvascular complications such as retinopathy and nephropathy, no marked effect has been reported on macrovascular complications or all-cause mortality. Evidence from VADT, ACCORD, and ADVANCE would suggest that glycemic control has little effect on macrovascular outcomes. Moreover, in the case of ACCORD, intensive glycemic control may be associated with an increased risk of mortality. There is sufficient evidence that suggests that postprandial hyperglycemia may be an independent risk factor for cardiovascular disease in diabetes patients. However, there are no prospective clinical trials supporting the recommendation that lowering postprandial blood glucose leads to lower risk of cardiovascular outcomes. Mitiglinide is a short-acting insulinotropic agent used in type 2 diabetes treatment. It has a rapid stimulatory effect on insulin secretion and reduces postprandial plasma glucose level in patients with type 2 diabetes. Because of its short action time, it is unlikely to exert adverse effects related to hypoglycemia early in the morning and between meals. Mitiglinide reduces excess oxidative stress and inflammation, plays a cardioprotective role, and improves postprandial metabolic disorders. Moreover, mitiglinide add-on therapy with pioglitazone favorably affects the vascular endothelial function in type 2 diabetes patients. These data suggest that mitiglinide plays a potentially beneficial role in the improvement of postprandial hyperglycemia in type 2 diabetes patients and can be used to prevent cardiovascular diseases. Although the results of long-term, randomized, placebo-controlled trials for determining the cardiovascular effects of mitiglinide on clinical outcomes are awaited, this review is aimed at summarizing substantial insights into this topic.</p